about
Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles.DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor ImmunityChimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.NK cell receptors as tools in cancer immunotherapy.An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivoChimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myelomaNKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model.Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function.Enhanced tumor immunogenicity through coupling cytokine expression with antigen presentation.NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo.Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model
P50
Q35168522-935EBB23-3207-4798-8A9F-3A2D0604D044Q35209066-0584FCE1-6C68-4BE3-B7DD-5C8ABA7CD19CQ35613233-CE1B9709-FF7C-4433-B2B2-4734FBDF202EQ35848101-E4047F1D-15DA-4574-A610-3334082BBFE3Q35929030-F435CBB4-42DA-416C-95A5-C7279EBC405EQ36543814-DC578A30-F978-4ABC-83AA-A213B52ECD05Q36787587-AFEA08AD-3A34-4F86-89BA-D544C4185B7FQ37089674-AD81E8C2-C485-45D5-BA52-1BEFF61114B2Q38788557-3AEC8311-DE08-43B8-992B-48876E7BFBB9Q39203569-8536B985-3E5D-42B3-B7B4-807D0FDA485AQ40137938-2D934E08-ED41-4234-AEB8-F1FF93F03998Q40272715-B187D207-797F-4F29-B0AD-7A8423028A20Q40553796-3B74DEF2-A4CA-4474-95B6-CE9074380E45Q40639521-D5F6EEA3-2C8C-444B-A607-7092BA1B0B7EQ50712190-BF62160C-9BCE-46D5-8F3F-1430573E7602Q81343892-FE7C9625-FC8F-4842-8DEA-FCCC42A2181B
P50
description
researcher, BeiGene, 0000-0002-9657-5129
@en
name
Tong Zhang
@en
Tong Zhang
@nl
type
label
Tong Zhang
@en
Tong Zhang
@nl
prefLabel
Tong Zhang
@en
Tong Zhang
@nl
P31
P496
0000-0002-9657-5129